News and Announcements
Streamlining the Capital Raising Process: Lessons from Blockbuster and Netflix
- Published April 06, 2023 2:40AM UTC
- Publisher Jade Miguel
- Categories Capital Raising Tips
If you’re old enough, you may recall the nostalgic experience of visiting your local Blockbuster video store on weekends. While those memories make us smile, Blockbuster’s downfall illustrates the importance of market efficiency. In just six years, Netflix emerged as a game-changer, offering instant access to movies and leading Blockbuster to bankruptcy.
Similarly, inefficiencies can plague the capital-raising process, costing you time, money, and opportunities. To improve efficiency, consider the following areas:
- Pitch deck and its structure
- Investor communications
- Deal room materials for investors
- Investor meeting structure and conversion rate
- Attracting and qualifying investors
- Conversion rate from potential investors to actual investors
- Understanding key interests of potential investors
By addressing these seven areas, you could potentially secure an additional $500,000 for your business or save six months of fundraising time. Here are some recommendations for founders seeking to create efficiency in their capital raising process:
- Plan a strategic capital raising campaign that spans at least six months.
- Gamify the process by understanding your numbers and conversion rates.
- Treat recurring questions as mistakes in your process that need to be fixed.
- Set target benchmarks for yourself to achieve.
- Be diligent in your efforts, remembering the adage, “The harder I work, the luckier I get.”
- Your goal should be to reach a ‘yes’ or ‘no’ decision as quickly as possible, respecting both your time and your potential investors’ time.
In upcoming articles, we will discuss specific activities to save up to a month of your time each year and minimise revenue and opportunity costs in the capital-raising process.
Capital Raising Tips
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
